Cargando…

Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020

Our aim was to assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection after the lockdown in a sample of the Corsican population. Between 16 April and 15 June 2020, 2312 residual sera were collected from patients with a blood analysis conducted in one of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Capai, Lisandru, Ayhan, Nazli, Masse, Shirley, Canarelli, Jean, Priet, Stéphane, Simeoni, Marie-Hélène, Charrel, Remi, de Lamballerie, Xavier, Falchi, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694549/
https://www.ncbi.nlm.nih.gov/pubmed/33167563
http://dx.doi.org/10.3390/jcm9113569
_version_ 1783615002134970368
author Capai, Lisandru
Ayhan, Nazli
Masse, Shirley
Canarelli, Jean
Priet, Stéphane
Simeoni, Marie-Hélène
Charrel, Remi
de Lamballerie, Xavier
Falchi, Alessandra
author_facet Capai, Lisandru
Ayhan, Nazli
Masse, Shirley
Canarelli, Jean
Priet, Stéphane
Simeoni, Marie-Hélène
Charrel, Remi
de Lamballerie, Xavier
Falchi, Alessandra
author_sort Capai, Lisandru
collection PubMed
description Our aim was to assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection after the lockdown in a sample of the Corsican population. Between 16 April and 15 June 2020, 2312 residual sera were collected from patients with a blood analysis conducted in one of the participating laboratories. Residual sera obtained from persons of all ages were tested for the presence of anti-SARS-CoV-2 Immunoglobulin G (IgG) using the EUROIMMUN enzyme immunoassay kit for semiquantitative detection of IgG antibodies against the S1 domain of viral spike protein (ELISA-S). Borderline and positive samples in ELISA-S were also tested with an in-house virus neutralization test (VNT). Prevalence values were adjusted for sex and age. A total of 1973 residual sera samples were included in the study. The overall seroprevalence based on ELISA-S was 5.27% (95% confidence interval (CI), 4.33–6.35) and 5.46% (4.51–6.57) after adjustment. Sex was not associated with IgG detection. However, significant differences were observed between age groups (p-value = 1 E-5). The highest values were observed among 10–19, 30–39, and 40–49 year-old age groups, ranging around 8–10%. The prevalence of neutralizing antibody titers ≥40 was 3% (2.28–3.84). In conclusion, the present study showed a low seroprevalence for COVID-19 in Corsica, a finding that is in accordance with values reported for other French regions in which the impact of the pandemic was low.
format Online
Article
Text
id pubmed-7694549
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76945492020-11-28 Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020 Capai, Lisandru Ayhan, Nazli Masse, Shirley Canarelli, Jean Priet, Stéphane Simeoni, Marie-Hélène Charrel, Remi de Lamballerie, Xavier Falchi, Alessandra J Clin Med Article Our aim was to assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection after the lockdown in a sample of the Corsican population. Between 16 April and 15 June 2020, 2312 residual sera were collected from patients with a blood analysis conducted in one of the participating laboratories. Residual sera obtained from persons of all ages were tested for the presence of anti-SARS-CoV-2 Immunoglobulin G (IgG) using the EUROIMMUN enzyme immunoassay kit for semiquantitative detection of IgG antibodies against the S1 domain of viral spike protein (ELISA-S). Borderline and positive samples in ELISA-S were also tested with an in-house virus neutralization test (VNT). Prevalence values were adjusted for sex and age. A total of 1973 residual sera samples were included in the study. The overall seroprevalence based on ELISA-S was 5.27% (95% confidence interval (CI), 4.33–6.35) and 5.46% (4.51–6.57) after adjustment. Sex was not associated with IgG detection. However, significant differences were observed between age groups (p-value = 1 E-5). The highest values were observed among 10–19, 30–39, and 40–49 year-old age groups, ranging around 8–10%. The prevalence of neutralizing antibody titers ≥40 was 3% (2.28–3.84). In conclusion, the present study showed a low seroprevalence for COVID-19 in Corsica, a finding that is in accordance with values reported for other French regions in which the impact of the pandemic was low. MDPI 2020-11-05 /pmc/articles/PMC7694549/ /pubmed/33167563 http://dx.doi.org/10.3390/jcm9113569 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Capai, Lisandru
Ayhan, Nazli
Masse, Shirley
Canarelli, Jean
Priet, Stéphane
Simeoni, Marie-Hélène
Charrel, Remi
de Lamballerie, Xavier
Falchi, Alessandra
Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020
title Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020
title_full Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020
title_fullStr Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020
title_full_unstemmed Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020
title_short Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020
title_sort seroprevalence of sars-cov-2 igg antibodies in corsica (france), april and june 2020
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694549/
https://www.ncbi.nlm.nih.gov/pubmed/33167563
http://dx.doi.org/10.3390/jcm9113569
work_keys_str_mv AT capailisandru seroprevalenceofsarscov2iggantibodiesincorsicafranceaprilandjune2020
AT ayhannazli seroprevalenceofsarscov2iggantibodiesincorsicafranceaprilandjune2020
AT masseshirley seroprevalenceofsarscov2iggantibodiesincorsicafranceaprilandjune2020
AT canarellijean seroprevalenceofsarscov2iggantibodiesincorsicafranceaprilandjune2020
AT prietstephane seroprevalenceofsarscov2iggantibodiesincorsicafranceaprilandjune2020
AT simeonimariehelene seroprevalenceofsarscov2iggantibodiesincorsicafranceaprilandjune2020
AT charrelremi seroprevalenceofsarscov2iggantibodiesincorsicafranceaprilandjune2020
AT delamballeriexavier seroprevalenceofsarscov2iggantibodiesincorsicafranceaprilandjune2020
AT falchialessandra seroprevalenceofsarscov2iggantibodiesincorsicafranceaprilandjune2020